Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Legend Biotech develops and sells engineered cell therapies that fight cancer, mainly multiple myeloma.
Legend Biotech makes a living selling a living drug. It takes a patient's own immune cells, engineers them in a lab to hunt cancer, and infuses them back. This is CAR-T therapy: instead of a bottle of pills, the treatment is a batch of the patient's own reprogrammed T cells, custom-built for one person at a time.
The company's big product is Carvykti, a one-time treatment for multiple myeloma, a cancer of the plasma cells in the bone marrow. Legend developed it with Johnson & Johnson, which handles much of the manufacturing and commercialization outside Greater China. That partnership matters enormously: J&J's sales machine and deep pockets help Carvykti reach patients worldwide, while Legend shares in the economics. The two are also testing Carvykti earlier in the disease, in patients who have had fewer prior treatments, which could open a much larger market if regulators agree. Behind the science sits a hard business problem. Every dose is a tiny manufacturing project — collect a patient's cells, ship them, engineer them, test them, freeze them, and get them back to the right hospital. Capacity is the bottleneck, and Legend and its partner have been spending heavily to expand it. That spending, plus the cost of running clinical trials, is why the company has been burning cash and posting losses while revenue climbs. Legend also has a pipeline of other cell therapies in earlier stages, including work in solid tumors and autoimmune disease, though those are still bets rather than businesses.
The stock is a wager on Carvykti's continued growth and on whether earlier-line use pans out. Risks are real: competition from other myeloma drugs, manufacturing stumbles, trial setbacks, and the fact that the company depends heavily on one product and one partner. Legend is headquartered in Somerset, New Jersey, with major operations in China, reflecting its origins as a spinout of the Chinese biotech GenScript.
Saved answer · last researched 15 Nov 2026